Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has a rich pipeline reserve that lays the foundation for growth, with a focus on product sales progress [1] - The company is expected to achieve a net profit of 1.423 billion yuan in 2026, corresponding to a PE ratio of 27.4 times [7] - The company is pursuing a dual strategy of "R&D + M&A" to drive growth, with a strong emphasis on new product approvals and international business integration [7] Financial Performance Summary - For 2025, the company reported revenue of 2.453 billion yuan, a decrease of 18.9% year-on-year, and a net profit of 1.291 billion yuan, down 34.1% [7] - The core product revenue saw a decline, with solution-type injection products generating 1.265 billion yuan (down 27.5%) and gel-type injection products generating 890 million yuan (down 26.8%) [7] - The company has a comprehensive gross profit margin of 92.7% for 2025, which is a decrease of 1.9 percentage points [7] Earnings Forecast - Projected revenues for the years 2024 to 2028 are as follows: 3.026 billion yuan (2024), 2.453 billion yuan (2025), 2.775 billion yuan (2026), 3.058 billion yuan (2027), and 3.116 billion yuan (2028) [6] - The expected net profit for the years 2026 to 2028 is 1.423 billion yuan (2026), 1.582 billion yuan (2027), and 1.635 billion yuan (2028) [7] - The company’s return on equity (ROE) is projected to be 17.1% in 2026, decreasing to 16.3% by 2028 [6] Product Pipeline and Strategic Initiatives - The company has a robust pipeline with 12 Class III medical device product registrations, including the recently approved botulinum toxin type A and minoxidil solution [7] - The launch of the new product "Kakola" in May 2025 aims to enhance the product portfolio in facial contouring treatments [7] - The company has made strategic acquisitions, including REGEN in South Korea, to deepen its international strategy and enhance its regenerative product matrix [7]

Core Viewpoint - The listing process of Zhongjian Health Bridge Pharmaceutical Group Co., Ltd. is at a critical juncture, highlighting the company's focus on chronic disease management, particularly in cardiovascular medications, as it seeks to leverage capital market opportunities for growth [1][4]. Group 1: Company Overview - Zhongjian Health Bridge is a modern comprehensive pharmaceutical enterprise that focuses on the chronic disease sector, with a core emphasis on cardiovascular medications [1]. - The company has successfully identified and addressed clinical pain points, particularly the gastrointestinal side effects associated with traditional aspirin, by launching its core product, aluminum magnesium aspirin tablets (II) [3]. Group 2: Product Development and Market Position - The aluminum magnesium aspirin tablets (II) is not merely a generic product; it combines aspirin with magnesium carbonate and aluminum hydroxide to reduce gastrointestinal adverse effects while maintaining antiplatelet efficacy [3]. - This product has achieved significant sales growth, with revenue surpassing 400 million yuan in 2024, and it has established a strong market presence across over 12,000 terminals [3]. Group 3: Financial Performance - From 2022 to 2024, the company's revenue increased from 268 million yuan to 447 million yuan, with a gross margin consistently above 90%, reaching 92.66% in 2024 [4]. - The net profit attributable to the parent company reached 103 million yuan in 2024, with net cash flow from operating activities at 111 million yuan, indicating strong profitability and cash flow alignment [4]. Group 4: Growth Strategy - Zhongjian Health Bridge is not solely reliant on its flagship product; it is pursuing a dual strategy of "R&D + M&A" to build a diversified product portfolio and mitigate risks [4]. - The company has successfully acquired drug registration certificates and related technologies for hydrochloride alprostadil tablets and sodium fusidate for injection, enhancing its product offerings in hypertension and infection treatment [4]. Group 5: Research and Development - The company maintains a long-term commitment to independent research and development, with established technology centers in Xi'an and Linyi [5]. - Currently, Zhongjian Health Bridge has five core technology platforms and is developing one class 1 new drug and six class 2 new drugs, including a significant product in the anti-epileptic field, sodium valproate sustained-release tablets [5]. Group 6: Future Outlook - The upcoming listing on the Beijing Stock Exchange represents a pivotal moment for Zhongjian Health Bridge as it transitions from a single-product focus to a modern comprehensive pharmaceutical group [5]. - The feedback from the second round of inquiries will provide clearer insights into how the company plans to utilize capital market resources to expand capacity and accelerate R&D in the growing chronic disease management sector [5].